Codis Expands UK Facility with GEA PSD4 Solvent Spray Dryer for Advanced Manufacturing
In a remarkable move that underscores its leadership in the pharmaceutical manufacturing landscape, Codis, a prominent contract development and manufacturing organization (CDMO) specializing in spray drying and amorphous solid dispersions (ASDs), has announced a major expansion of its operational capabilities in Haverhill, UK. The company is investing in a GEA Pharma-SD® type PSD-4 solvent-capable spray dryer, which will make Codis the only UK CDMO to offer such cutting-edge commercial-scale manufacturing technology.
This strategic investment will enable Codis to enhance its production capacity for solvent-based spray drying, a crucial process that significantly improves the bioavailability of poorly soluble drug candidates. By utilizing the superior technology of the PSD4, Codis can produce commercial batches up to 500 kg with an impressive total annual capacity of 30,000 kg. This initiative not only responds to the burgeoning demand for innovative pharmaceutical solutions but also highlights the company's commitment to bringing life-changing medicines to market more efficiently.
Supported by the UK government's Life Sciences Innovative Manufacturing Fund (LSIMF), Codis' initiative is set to accelerate the expansion project, which is expected to be operational by 2027. The LSIMF offers substantial capital grants—up to £520 million—to bolster growth in the life sciences sector, which further validates the significance of this development in UK's economic context. The funding not only aids in enhancing manufacturing capabilities but also fosters local job creation during the construction, installation, and commissioning phases of the new equipment.
Nicolas Fortin, the Chief Executive Officer of Codis, expressed enthusiasm regarding this pivotal addition, stating, "The PSD4 significantly expands our ASD capacity and gives customers dedicated commercial-scale throughput to bring more life-changing medicines to market. We are grateful for the support of the UK government through the LSIMF, which enables us to accelerate this project and continue investing at our Haverhill site." This sentiment reflects Codis' vision of integrating advanced manufacturing technology with development processes, ensuring a seamless transition from research to commercial production.
The new facility is set to create not only immediate temporary jobs but also sustainable long-term positions as Codis ramps up production. Moreover, the project hinges on collaboration with local suppliers and contractors, enhancing the regional life sciences ecosystem and contributing to sustained economic development. Codis’ existing infrastructure at the 400,000-square-foot Haverhill site already plays a significant role in advanced particle engineering, and this new acquisition will further cement its reputation as a key player within the industry.
Codis operates with state-of-the-art facilities not just in the UK but also in St. Louis, Missouri, and Seymour, Indiana, covering more than 400,000 sq ft dedicated to cGMP (current Good Manufacturing Practices) compliance. This combined expertise and regulatory experience fortify Codis' position as a trusted partner for pharmaceutical, consumer health, nutraceutical, and OTC sectors.
As Codis progresses with the PSD4 installation, the potential for rapid technological advancements and increased production capabilities paints an optimistic future for the pharmaceutical industry. Companies looking to enhance their drug development processes and mitigate time-to-market challenges will find valuable opportunities through Codis’ expanded services. This significant milestone reiterates Codis' commitment to innovation and its unwavering focus on enhancing healthcare outcomes through advanced manufacturing solutions.
For more information about Codis and its extensive service offerings, you can visit their official website at www.codis.com.
This strategic investment will enable Codis to enhance its production capacity for solvent-based spray drying, a crucial process that significantly improves the bioavailability of poorly soluble drug candidates. By utilizing the superior technology of the PSD4, Codis can produce commercial batches up to 500 kg with an impressive total annual capacity of 30,000 kg. This initiative not only responds to the burgeoning demand for innovative pharmaceutical solutions but also highlights the company's commitment to bringing life-changing medicines to market more efficiently.
Supported by the UK government's Life Sciences Innovative Manufacturing Fund (LSIMF), Codis' initiative is set to accelerate the expansion project, which is expected to be operational by 2027. The LSIMF offers substantial capital grants—up to £520 million—to bolster growth in the life sciences sector, which further validates the significance of this development in UK's economic context. The funding not only aids in enhancing manufacturing capabilities but also fosters local job creation during the construction, installation, and commissioning phases of the new equipment.
Nicolas Fortin, the Chief Executive Officer of Codis, expressed enthusiasm regarding this pivotal addition, stating, "The PSD4 significantly expands our ASD capacity and gives customers dedicated commercial-scale throughput to bring more life-changing medicines to market. We are grateful for the support of the UK government through the LSIMF, which enables us to accelerate this project and continue investing at our Haverhill site." This sentiment reflects Codis' vision of integrating advanced manufacturing technology with development processes, ensuring a seamless transition from research to commercial production.
The new facility is set to create not only immediate temporary jobs but also sustainable long-term positions as Codis ramps up production. Moreover, the project hinges on collaboration with local suppliers and contractors, enhancing the regional life sciences ecosystem and contributing to sustained economic development. Codis’ existing infrastructure at the 400,000-square-foot Haverhill site already plays a significant role in advanced particle engineering, and this new acquisition will further cement its reputation as a key player within the industry.
Codis operates with state-of-the-art facilities not just in the UK but also in St. Louis, Missouri, and Seymour, Indiana, covering more than 400,000 sq ft dedicated to cGMP (current Good Manufacturing Practices) compliance. This combined expertise and regulatory experience fortify Codis' position as a trusted partner for pharmaceutical, consumer health, nutraceutical, and OTC sectors.
As Codis progresses with the PSD4 installation, the potential for rapid technological advancements and increased production capabilities paints an optimistic future for the pharmaceutical industry. Companies looking to enhance their drug development processes and mitigate time-to-market challenges will find valuable opportunities through Codis’ expanded services. This significant milestone reiterates Codis' commitment to innovation and its unwavering focus on enhancing healthcare outcomes through advanced manufacturing solutions.
For more information about Codis and its extensive service offerings, you can visit their official website at www.codis.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.